


JUN 13 2003

TECH CENTER 1600/2900

RECEIVED

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10244A	SERIAL NO. 09/528,798 ⁹⁷⁸
		APPLICANT R. S. Obach	
		FILING DATE March 21, 2000	GROUP unknown

340	W.D. Paar <i>et al.</i> , "Polymorphic CYP2D6 mediates O-demethylation of the opoid analgesic tramadol", 12 <i>Eur. J. Clin. Pharm.</i> , 53, 235-239 (1997)
	E. Lessard <i>et al.</i> , "Role of CYP2D6 in the N-hydroxylation of procainamide", <i>Pharmacogenetics</i> , 7, 381-90 (1997);
	L.Y. Lin <i>et al.</i> , "Oxidation of Methamphetamine and Methylenedioxyamphetamine by CYP2D6", <i>Drug Metab. Dispos.</i> , 25, 1059-64 (1997)
	hangata Dehal <i>et al.</i> , "CYP2D6 Catalyzes Tamoxifen-Hydroxylation in Human Liver", <i>Cancer Res.</i> , 57, 3402-06 (1997)
	Y. Bottiger <i>et al.</i> , "Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans", <i>Br. J. Pharm.</i> , 42, 707-11 (1996)
	B. A. Hamelin <i>et al.</i> , "The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin", <i>Clin. Pharmacol. Ther.</i> , 60, 512-21 (1996)
	M. F. Fromm <i>et al.</i> , "Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs", in <i>Advanced Drug Delivery Reviews</i> , 27, 171-199 (1997)
	V. Ozdemir, <i>et al.</i> , "The Extent and Determinants of Changes in CYP2D6 and CYP1A2 Activities with Therapeutic Doses of Sertraline", <i>J. Clin. Psychopharm.</i> , 18, 55-61 (1998)
	S.E. Ball <i>et al.</i> , Venlafaxine: <i>in vitro</i> inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", <i>Br. J. Pharm.</i> , 43, 619-26 (1997)
	A.D. Rodrigues, "The <i>In Vitro</i> Interaction of Dexmedetomidine with Human Liver Microsomal Cytochrome P4502D6", <i>Drug Metabolism and Disposition</i> , 25, 651-55 (1997)
T. Prueksaritanont <i>et al.</i> , " <i>In Vitro</i> and <i>In Vivo</i> Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and its Carboxyl Ester Prodrug L-775,318, <i>Drug Metabolism and Disposition</i> , 26, 531-39 (1998)	
O.O. Simooya <i>et al.</i> , "Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians", <i>Br. J. Clin. Pharm.</i> , 45, 315-(1998);	
Sebastian Härtter <i>et al.</i> , "Inhibition of dextromethorphan metabolism by moclobemide", <i>Psychopharm.</i> , 135, 22-26 (1998)	

EXAMINER	DATE CONSIDERED
	10/9/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

JUN 13 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10244A		SERIAL NO. 09/528, ⁹⁷⁸ 798	
		APPLICANT R. S. Obach			
		FILING DATE March 21, 2000		GROUP unknown	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
FOREIGN PATENT DOCUMENTS					
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<p>B. Schmidt <i>et al.</i>, "Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation", <i>Clin. Pharmacol. Ther.</i>, 38, 618 (1985)</p> <p>K. Nakamura, <i>et al.</i>, "Oxidation of Histamine H1 Antagonist Mequitazine is Catalyzed by Cytochrome P450 2D6 in Human Liver Microsomes", <i>J. Pharmacol. Exp. Ther.</i>, 284, 437-442 (1998)</p> <p>H. Kamimura <i>et al.</i>, "Identification of cytochrome P450 isozymes involved in metabolism of the α_1 adrenocceptor blocker tamsulosin in human liver microsomes", <i>Xenobiotica</i>, 28, 909-22 (1998)</p> <p>M. Yaïch <i>et al.</i>, "In vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans", <i>Pharmacogen.</i>, 8, 449-51 (1998)</p> <p>A.E. Mutlib <i>et al.</i>, "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone", <i>J. Pharmacol. Exp. Ther.</i>, 286, 1285-93 (1998)</p> <p>R. Scott Orbach, <i>et al.</i>, "Cytochrome P4502D6 Catalyzes the O-Demethylation of the Psychoactive Alkaloid Ibogaine to 12-Hydroxyibogamine", <i>Drug Metab. Dispos.</i>, 26, 764-8 (1998).</p> <p>R.L. Voorman, <i>et al.</i>, Metabolism of Delavirdine, A Human Immunodeficiency virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A, <i>Drug Metab. Dispos.</i>, 26, 631-9 (1998).</p> <p>N. Brynne <i>et al.</i>, "Influence CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine", <i>Clin. Pharmacol. Ther.</i>, 63, 529-39 (1998)</p> <p>Rinshoyakon, 29, 231-38 (1998)</p> <p>Z. Desta, <i>et al.</i>, "Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide", <i>J. Pharmacol. Exp. Ther.</i>, 285, 428-37 (1998)</p> <p>W. Kishimoto <i>et al.</i>, "Metabolism of Epinastine, a Histamine H1 Receptor Antagonist, in Human Liver Microsomes in Comparison with that of Terfenadine", <i>Res. Comm. Md. Path. Pharmacol.</i>, 98, 273-92 (1997)</p>					